Methods for treating multiple myeloma
AssigneeJanssen Pharmaceutica NV
InventorsSuzette Girgis, Jenna Goldberg, Brandi Hilder, Xuewen Ma, Jeffery Russell, Raluca Verona, Shiyi Yang, Kodandaram Pillarisetti
Life of this patent
Estimating the term…
Abstract
Methods of treating a hematological malignancy using a GPRC5D×CD3 bispecific antibody are described. The hematological malignancy can be a relapsed or refractory multiple myeloma, and the GPRC5D×CD3 bispecific antibody can be talquetamab.
Claims23
A method of treating a hematological malignancy, preferably a multiple myeloma, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a GPRC5D×CD3 bispecific antibody or antigen binding fragment thereof, wherein the subject is relapsed or refractory to treatment with a prior anti-cancer treatment.
A method of treating a multiple myeloma in a subject in need thereof, comprising subcutaneously administering to the subject 405 μg/kg of a GPRC5D×CD3 bispecific antibody or antigen binding fragment thereof weekly or biweekly, wherein the subject is relapsed or refractory to treatment with a prior anti-cancer treatment, preferably the initial administration of the 405 μg/kg GPRC5D×CD3 bispecific antibody or antigen binding fragment thereof occurs after the subject is administered with one or more priming doses of the antibody or antigen binding fragment thereof, such as one or more priming doses of 10, 60, and 300 μg/kg administered subcutaneously weekly or biweekly.
A method of treating a multiple myeloma in a subject in need thereof, comprising subcutaneously administering to the subject 800 μg/kg of a GPRC5D×CD3 bispecific antibody or antigen binding fragment thereof weekly or biweekly, wherein the subject is relapsed or refractory to treatment with a prior anti-cancer treatment, preferably the initial administration of the 800 μg/kg GPRC5D×CD3 bispecific antibody or antigen binding fragment thereof occurs after the subject is administered with one or more priming doses of the antibody or antigen binding fragment thereof, such as one or more priming doses of 10, 60, and 300 μg/kg administered subcutaneously weekly or biweekly.
Dependencies are inferred from the claim text.